KMPH Stock Analysis

KMPH -  USA Stock  

USD 15.47  1.54  11.06%

The current price rise of Kempharm may raise some interest from stockholders. The stock closed today at a share price of 15.47 on 1,264,105 in trading volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in July. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.02. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Kempharm partners.
Please see Stocks Correlation.

Search Stock Analysis 

The Kempharm stock analysis report makes it easy to digest most publicly released information about Kempharm and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. KMPH stock analysis module also helps to analyze the Kempharm price relationship with some important fundamental indicators such as market cap and management efficiency.

KMPH Stock Analysis Notes

The company recorded a loss per share of 3.2. Kempharm had not issued any dividends in recent years. The entity had a split on the 28th of December 2020. KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people. To find out more about Kempharm contact Travis Mickle at 321 939 3416 or learn more at

Kempharm Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Kempharm's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Kempharm or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Kempharm has very high historical volatility over the last 90 days
Kempharm has high likelihood to experience some financial distress in the next 2 years
Kempharm was previously known as Kempharm and was traded on NASDAQ Exchange under the symbol KMPHD.
The company reported the previous year's revenue of 13.29 M. Net Loss for the year was (12.76 M) with profit before overhead, payroll, taxes, and interest of 11.98 M.
Kempharm currently holds about 4.21 M in cash with (1.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.15.
Kempharm has a frail financial position based on the latest SEC disclosures
Latest headline from KemPharm Issues Letter to Shareholders - GlobeNewswire

Kempharm Upcoming and Recent Events

Earnings reports are used by Kempharm to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kempharm previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report11th of August 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End10th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

KMPH Largest EPS Surprises

Earnings surprises can significantly impact Kempharm's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Kempharm SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Kempharm prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Kempharm investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Kempharm specific information freely available to individual and institutional investors to make a timely investment decision.
16th of June 2021
Financial Statements and Exhibits. Regulation FD Disclosure
17th of May 2021
Unclassified Corporate Event
13th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
19th of April 2021
Unclassified Corporate Event
8th of April 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Entry into a Material Definitive Agreement
11th of March 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
9th of March 2021
Unclassified Corporate Event
3rd of March 2021
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure

KMPH Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Kempharm is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kempharm backward and forwards among themselves. Kempharm's institutional investor refers to the entity that pools money to purchase Kempharm's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Vanguard Group IncCommon Shares817.8 K7.5 M
Sabby Management LlcPut OptionsK4.6 M
Sabby Management LlcCall Options4.2 K3.9 M
Millennium Management LlcCommon Shares212.7 KM
Susquehanna International Group LlpCommon Shares197.1 K1.8 M
Geode Capital Management LlcCommon Shares178 K1.6 M
Jane Street Group LlcCommon Shares159.7 K1.5 M
Citadel Advisors LlcCommon Shares157.5 K1.4 M
Harel Insurance Investments Financial Services LtdCommon Shares20 K615 K
Note, although Kempharm's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

KMPH Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 440.73 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kempharm's market, we take the total number of its shares issued and multiply it by Kempharm's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

KMPH Profitablity

Kempharm's profitability indicators refer to fundamental financial ratios that showcase Kempharm's ability to generate income relative to its revenue or operating costs. If, let's say, Kempharm is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Kempharm's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Kempharm's profitability requires more research than a typical breakdown of Kempharm's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (96.03) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (35.98) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.36.
Last ReportedProjected for 2021
Return on Average Assets(1.17) (1.26) 
Return on Average Equity 0.20  0.20 
Return on Invested Capital(0.41) (0.44) 
Return on Sales(0.60) (0.65) 

Management Efficiency

The entity has return on total asset (ROA) of (27.52) % which means that it has lost $27.52 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (222.16) %, meaning that it created substantial loss on money invested by shareholders. Kempharm management efficiency ratios could be used to measure how well kempharm manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Average Equity is estimated to increase to 0.20, while Return on Average Assets are projected to decrease to (1.26) . Kempharm Assets Non Current are most likely to increase significantly in the upcoming years. The last year's value of Assets Non Current was reported at 2.83 Million. The current Asset Turnover is estimated to increase to 1.26, while Return on Average Assets are projected to decrease to (1.26) .
Last ReportedProjected for 2021
Book Value per Share(16.68) (18.00) 
Enterprise Value over EBIT(14.00) (14.37) 
Enterprise Value over EBITDA(14.74) (15.13) 
Price to Book Value(0.77) (0.82) 
Tangible Assets Book Value per Share 2.82  2.89 
Enterprise Value114 M118.9 M
Tangible Asset Value11.2 M11.5 M

Technical Drivers

As of the 20th of June, Kempharm secures the Downside Deviation of 4.13, mean deviation of 3.04, and Risk Adjusted Performance of 0.1047. Kempharm technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Kempharm, which can be compared to its peers in the industry. Please verify Kempharm coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Kempharm is priced some-what accurately, providing market reflects its recent price of 15.47 per share. Given that Kempharm has jensen alpha of 0.5876, we recommend you to check Kempharm's last-minute market performance to make sure the company can sustain itself at a future point.

Kempharm Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. View also all equity analysis or get more info about mavp overlap studies indicator.

Kempharm Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kempharm insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kempharm's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kempharm insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Kempharm Technical and Predictive Indicators

Kempharm Forecast Models

Kempharm time-series forecasting models is one of many Kempharm's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kempharm's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Kempharm Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Kempharm stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling KMPH shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Kempharm. By using and applying KMPH Stock analysis, traders can create a robust methodology for identifying KMPH entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(0.58) (0.63) 
Gross Margin 0.90  0.89 
Profit Margin(0.96) (1.04) 
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.

Current KMPH Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. KMPH analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. KMPH analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Kempharm current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most KMPH analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand KMPH stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Kempharm, talking to its executives and customers, or listening to KMPH conference calls.
KMPH Analyst Advice Details

KMPH Stock Analysis Indicators

Kempharm stock analysis indicators help investors evaluate how Kempharm stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Kempharm shares will generate the highest return on investment. By understating and applying Kempharm stock analysis, traders can identify Kempharm position entry and exit signals to maximize returns.
Quick Ratio0.90
Fifty Two Week Low3.06
Revenue Growth71.90%
Shares Short Prior Month2.61M
Average Daily Volume Last 10 Day1.31M
Average Daily Volume In Three Month1.58M
Shares Percent Shares Out11.73%
Gross Margins90.18%
Short Percent Of Float11.80%
Forward Price Earnings309.40
Float Shares25.46M
Fifty Two Week High22.08
Enterprise Value To Ebitda-72.63
Fifty Day Average10.16
Two Hundred Day Average10.27
Enterprise Value To Revenue24.64
Please see Stocks Correlation. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
The market value of Kempharm is measured differently than its book value, which is the value of KMPH that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.